Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biotech lags market rebound

Despite an upturn in the general markets on Monday, the BioCentury 100 was unable to recapture any portion of last Friday's 13 percent loss, as the index slipped a further 2 percent on Monday. The general

Read the full 365 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers